Simvastatin attenuates angiotensin II‑induced inflammation and oxidative stress in human mesangial cells

Fengxiang Zhang1, Dapeng Sun2, Junjiang Chen2

  • 1Department of Anatomy, China Medical University, Shenyang, Liaoning 110001, P.R. China.

Insights

Simvastatin effectively reduces inflammation and oxidative stress in human mesangial cells stimulated by angiotensin II. This study reveals simvastatin

Area of Science:

  • Nephrology and Pharmacology
  • Molecular Biology and Cellular Signaling

Background:

  • Chronic kidney disease (CKD) is characterized by inflammation and oxidative stress.
  • Angiotensin II (Ang II) exacerbates inflammation and oxidative stress in kidney cells.
  • Understanding therapeutic interventions for CKD is crucial.

Purpose of the Study:

  • To investigate the effects of simvastatin on Ang II-induced inflammation and oxidative stress in human mesangial cells (HMCs).
  • To elucidate the underlying molecular mechanisms of simvastatin's action in HMCs.

Main Methods:

  • Human mesangial cells (HMCs) were treated with varying concentrations of simvastatin followed by Ang II stimulation.
  • Quantitative polymerase chain reaction (qPCR) and western blotting were used to analyze gene and protein expression.
  • Dihydroethidium staining and enzyme-linked immunosorbent assay (ELISA) measured reactive oxygen species and prostaglandin E2 levels.

Main Results:

  • Simvastatin dose-dependently suppressed Ang II-induced mRNA expression of inflammatory markers (MCP-1, TNF-α, IL-1β, IL-6).
  • Simvastatin reduced reactive oxygen species, prostaglandin E2, and protein expression of COX-2, NADPH oxidase, and phosphorylated NF-κB p65.
  • Simvastatin significantly increased peroxisome proliferator-activated receptor γ (PPARγ) protein expression.

Conclusions:

  • Simvastatin mitigates inflammation and oxidative stress in Ang II-stimulated HMCs.
  • The protective effects involve modulation of COX-2, PPARγ, NF-κB, NADPH oxidase, and PKC signaling pathways.
  • Simvastatin demonstrates potential as a therapeutic agent for CKD by targeting key inflammatory and oxidative stress pathways.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K